121
Participants
Start Date
March 2, 2022
Primary Completion Date
May 1, 2027
Study Completion Date
May 1, 2028
XELOX
Starting from the first day of radiotherapy (set as day 0), the patient received a total of 4 courses of XELOX chemotherapy on days -42, -21, 42, and 63, including oxaliplatin 130 mg/m2, intravenous administration, d1, repeat every 3 weeks; and capecitabine 1000mg/m2, twice daily, d1-d14, repeat every 3 weeks.
Capecitabine monotherapy
During radiotherapy (Monday to Friday), capecitabine was administered at 1650 mg/m2/d, twice a day.
Radiation
The TV is expanded by 6-7mm to form PTV1, and the CTV is expanded by 6-7mm to form PTV2. The dose of PTV1 was 50Gy/25 times/35 days, and the dose of PTV2 was 45Gy/25 times/35 days, 5 times/week for a total of 5 weeks.
RECRUITING
Zhenhai Lu, Guangzhou
Zhen-Hai Lu
OTHER